From Nasdaq:

Validea’s Earnings Yield Investor model has upgraded HARMONY BIOSCIENCES HOLDINGS INC (HRMY) from 80% to 90% based on strong fundamentals and valuation. HRMY is a small-cap value stock in the Biotechnology & Drugs industry. Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases. Its product, WAKIX, is designed to increase histamine signaling in the brain for the treatment of excessive daytime sleepiness and cataplexy in adult patients with narcolepsy. The company also provides an investigational compound, HBS-102, and its product candidates include Zygel. The stock meets the strategy’s test with a neutral earnings yield and return on tangible capital, passing the final ranking. Joel Greenblatt is well-known for producing exceptional returns as a hedge fund manager. Validea is an investment research service that follows the strategies of investment legends such as Warren Buffett, Benjamin Graham, Peter Lynch, and Martin Zweig. For more information about Validea, visit their website.



Read more: Validea Joel Greenblatt Strategy Daily Upgrade Report – 1/18/2024